Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hypermarcas stock logo
HYPMY
Hypermarcas
$4.86
+1.2%
$4.44
$3.71
$5.50
$3.42B0.7328,491 shs4,647 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$75.71
-0.4%
$74.79
$32.00
$86.74
$12.51B0.381.84 million shs1.66 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$510.04
-4.6%
$488.41
$265.00
$615.00
$11.76B-1.04272,702 shs379,186 shs
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$55.88
$56.80
$55.88
$56.95
$11.53B0.231,399 shsN/A
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hypermarcas stock logo
HYPMY
Hypermarcas
+0.94%+4.41%+4.07%+11.61%+27.77%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-0.41%+0.57%-0.94%-12.47%+128.94%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-4.64%-0.72%-2.72%+6.79%+70.68%
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
0.00%0.00%-1.88%-14.61%-0.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hypermarcas stock logo
HYPMY
Hypermarcas
$4.86
+1.2%
$4.44
$3.71
$5.50
$3.42B0.7328,491 shs4,647 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$75.71
-0.4%
$74.79
$32.00
$86.74
$12.51B0.381.84 million shs1.66 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$510.04
-4.6%
$488.41
$265.00
$615.00
$11.76B-1.04272,702 shs379,186 shs
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$55.88
$56.80
$55.88
$56.95
$11.53B0.231,399 shsN/A
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hypermarcas stock logo
HYPMY
Hypermarcas
+0.94%+4.41%+4.07%+11.61%+27.77%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-0.41%+0.57%-0.94%-12.47%+128.94%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-4.64%-0.72%-2.72%+6.79%+70.68%
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
0.00%0.00%-1.88%-14.61%-0.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hypermarcas stock logo
HYPMY
Hypermarcas
3.00
BuyN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.86
Moderate Buy$99.3531.22% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.76
Moderate Buy$682.0733.73% Upside
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
3.33
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest HYPMY, IONS, MDGL, and RCDTF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Set Price Target$649.00
5/7/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Lower Price TargetBuy$587.00 ➝ $578.00
5/6/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Reiterated RatingBuy$620.00
4/30/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Reiterated RatingOutperform$111.00
4/30/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Boost Price TargetBuy$120.00 ➝ $125.00
4/30/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Boost Price TargetOverweight$106.00 ➝ $115.00
4/30/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Boost Price TargetOutperform$95.00 ➝ $100.00
4/29/2026
Hypermarcas stock logo
HYPMY
Hypermarcas
UpgradeHold
4/23/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Lower Price TargetBuy$110.00 ➝ $108.00
4/21/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Reiterated RatingSell (D-)
4/21/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Reiterated RatingSell (D-)
(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B2.48$0.47 per share10.27$3.54 per share1.37
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$944M13.25N/AN/A$2.97 per share25.49
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.27N/AN/A$26.54 per share19.22
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$2.96B3.89N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hypermarcas stock logo
HYPMY
Hypermarcas
$213.10M$0.4810.127.14N/A19.41%14.08%6.91%N/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$381.39M-$2.07N/AN/AN/A-30.91%-58.65%-10.07%N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.80N/A48.67N/A-27.32%-48.24%-25.52%N/A
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$501.80M$2.3923.35N/AN/A16.92%34.11%12.59%5/12/2026 (Estimated)

Latest HYPMY, IONS, MDGL, and RCDTF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.61-$3.25+$0.36-$3.25$301.05 million$311.34 million
4/29/2026Q1 2026
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A$0.10N/A$0.10N/A$383.13 million
4/29/2026Q1 2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$0.85-$0.56+$0.29-$0.56$195.57 million$246.00 million
3/31/2026Q4 2025
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
$0.8570$0.88+$0.0230$1.11$778.42 million$770.90 million
3/12/2026Q4 2025
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A$0.13N/A$0.13N/A$414.22 million
2/25/2026Q4 2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$1.23-$1.41-$0.18-$1.41$156.07 million$203.33 million
2/19/2026Q4 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$0.04-$2.57-$2.61-$2.57$310.36 million$321.08 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.132.68%N/A27.08%N/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hypermarcas stock logo
HYPMY
Hypermarcas
0.61
1.27
0.84
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.75
4.10
4.09
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.56
4.01
3.77
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
1.13
1.64
1.16
CompanyEmployeesShares OutstandingFree FloatOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481704.01 millionN/ANot Optionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,402165.26 million160.97 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.06 million18.10 millionOptionable
Recordati Industria Chimica E Farmaceutica S.P.A. stock logo
RCDTF
Recordati Industria Chimica E Farmaceutica
4,583206.30 millionN/ANot Optionable

Recent News About These Companies

Cvc cerca un partner per l’Opa su Recordati
Recordati sizes up €10.9bn CVC Capital acquisition offer
Recordati, precisazioni su rumor di mercato
Recordati sospesa in attesa di una nota

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$4.86 +0.06 (+1.15%)
As of 05/8/2026 03:06 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$75.71 -0.31 (-0.41%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$75.71 0.00 (0.00%)
As of 05/8/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$510.04 -24.82 (-4.64%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$517.11 +7.07 (+1.39%)
As of 05/8/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Recordati Industria Chimica E Farmaceutica stock logo

Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF

$55.88 0.00 (0.00%)
As of 05/8/2026

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.